|
P-2017-48
|
Epigentek Group Inc
|
EpiQuik Methyl-CpG Binding Domain Protein 2 ChIP Kit [48 reactions]
|
|
IP
|
|
|
P-9003-050
|
Epigentek Group Inc
|
Methylamp RNA Bisulfite Conversion Kit [50 reactions]
|
|
Sample Modification
|
|
|
HY-123023-25ug
|
MedChemexpress LLC
|
12(S)-HETE D8 [CAS 84807-90-9]
|
|
|
|
|
HY-140381-100mg
|
MedChemexpress LLC
|
Azide-PEG2-Ms [CAS 176520-23-3]
|
|
Cancer-programmed cell death
|
|
|
HY-140381-250mg
|
MedChemexpress LLC
|
Azide-PEG2-Ms [CAS 176520-23-3]
|
|
Cancer-programmed cell death
|
|
|
HY-140381-50mg
|
MedChemexpress LLC
|
Azide-PEG2-Ms [CAS 176520-23-3]
|
|
Cancer-programmed cell death
|
|
|
HY-138363-10mg
|
MedChemexpress LLC
|
Azido-PEG6-MS [CAS 352439-38-4]
|
|
Cancer-programmed cell death
|
|
|
HY-138363-100mg
|
MedChemexpress LLC
|
Azido-PEG6-MS [CAS 352439-38-4]
|
|
Cancer-programmed cell death
|
|
|
HY-138363-25mg
|
MedChemexpress LLC
|
Azido-PEG6-MS [CAS 352439-38-4]
|
|
Cancer-programmed cell death
|
|
|
HY-138363-5mg
|
MedChemexpress LLC
|
Azido-PEG6-MS [CAS 352439-38-4]
|
|
Cancer-programmed cell death
|
|
|
HY-138363-50mg
|
MedChemexpress LLC
|
Azido-PEG6-MS [CAS 352439-38-4]
|
|
Cancer-programmed cell death
|
|
|
HY-13010-10mg
|
MedChemexpress LLC
|
Laquinimod [CAS 248281-84-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13010-100mg
|
MedChemexpress LLC
|
Laquinimod [CAS 248281-84-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13010-5mg
|
MedChemexpress LLC
|
Laquinimod [CAS 248281-84-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13010-50mg
|
MedChemexpress LLC
|
Laquinimod [CAS 248281-84-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13010-500mg
|
MedChemexpress LLC
|
Laquinimod [CAS 248281-84-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-13010-1mL
|
MedChemexpress LLC
|
Laquinimod [CAS 248281-84-7] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
